公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 |
---|---|---|---|---|---|---|
2013 | SC-1, a sorafenib derivative, shows anti-tumor effects in osteogenic sarcoma cells | CHEN-TI WANG ; Lin C.-S.; Shiau C.-W.; Chu P.-Y.; Hsiao C.-C.; Chiang Y.-L.; Tai W.-T.; Chen K.-F. | Journal of Orthopaedic Research | 9 | 6 | |
2014 | SC-60, a dimer-based sorafenib derivative, shows a better anti-hepatocellular carcinoma effect than sorafenib in a preclinical hepatocellular carcinoma model | Tai W.-T.; Shiau C.-W.; Li Y.-S.; Chen Y.-L.; Chu P.-Y.; Huang J.-W.; Hsu C.-Y.; Hsu Y.-C.; PEI-JER CHEN ; Chen K.-F. | Molecular Cancer Therapeutics | 7 | 6 | |
2014 | Signal transducer and activator of transcription 3 as molecular therapy for non-small-cell lung cancer | Wang C.-Y.; Chao T.-T.; Tai W.-T.; Chang F.-Y.; Su W.-P.; Chen Y.-L.; Chen P.-T.; Weng C.-Y.; ANG YUAN ; Shiau C.-W.; CHONG-JEN YU ; Chen K.-F. | Journal of Thoracic Oncology | 11 | 11 | |
2011 | Signal transducer and activator of transcription 3 is a major kinase-independent target of sorafenib in hepatocellular carcinoma | Tai W.-T.; ANN-LII CHENG ; Shiau C.-W.; HSIANG-PO HUANG ; Huang J.-W.; PEI-JER CHEN ; Chen K.-F. | Journal of Hepatology | 146 | 140 | |
2015 | Sorafenib Action in Hepatitis B Virus X-Activated Oncogenic Androgen Pathway in Liver Through SHP-1 | Wang S.-H.; Shiou-Hwei Yeh ; Shiau C.-W.; Chen K.-F.; Lin W.-H.; Tsai T.-F.; Teng Y.-C.; DING-SHINN CHEN ; PEI-JER CHEN | Journal of the National Cancer Institute | 20 | 14 | |
2013 | Sorafenib and its derivative SC-49 sensitize hepatocellular carcinoma cells to CS-1008, a humanized anti-TNFRSF10B (DR5) antibody | Chen K.-F.; Chen H.-L.; Shiau C.-W.; Liu C.-Y.; Chu P.-Y.; Tai W.-T.; Ichikawa K.; PEI-JER CHEN ; ANN-LII CHENG | British Journal of Pharmacology | 16 | 13 | |
2011 | Sorafenib derivatives induce apoptosis through inhibition of STAT3 independent of Raf | Chen K.-F.; Tai W.-T.; Huang J.-W.; Hsu C.-Y.; Chen W.-L.; ANN-LII CHENG ; PEI-JER CHEN ; Shiau C.-W. | European Journal of Medicinal Chemistry | 32 | 29 | |
2010 | Sorafenib overcomes TRAIL resistance of hepatocellular carcinoma cells through the inhibition of STAT3 | Chen K.-F.; Tai W.-T.; TSUNG-HAO LIU ; HSIANG-PO HUANG ; Lin Y.-C.; Shiau C.-W.; Li P.-K.; PEI-JER CHEN ; ANN-LII CHENG | Clinical Cancer Research | 147 | 145 | |
2014 | STAT3 mediates regorafenib-induced apoptosis in hepatocellular carcinoma | Tai W.-T.; Chu P.-Y.; Shiau C.-W.; Chen Y.-L.; Li Y.-S.; Hung M.-H.; Chen L.-J.; PEI-LUNG CHEN ; Su J.-C.; Lin P.-Y.; Yu H.-C.; Chen K.-F. | Clinical Cancer Research | 79 | 72 | |
2012 | Synthesis and biological activity of obatoclax derivatives as novel and potent SHP-1 agonists | Su J.-C.; Chen K.-F.; Chen W.-L.; Liu C.-Y.; Huang J.-W.; Tai W.-T.; PEI-JER CHEN ; Kim I.; Shiau C.-W. | European Journal of Medicinal Chemistry | 20 | 19 | |
2017 | Targeting SHP-1-STAT3 signaling: A promising therapeutic approach for the treatment of cholangiocarcinoma | Hu M.-H.; Chen L.-J.; Chen Y.-L.; Tsai M.-S.; Shiau C.-W.; Chao T.-I.; Liu C.-Y.; JIA-HORNG KAO ; Chen K.-F. | Oncotarget | 17 | 15 | |
2014 | TD-19, an erlotinib derivative, induces epidermal growth factor receptor wild-type nonsmall-cell lung cancer apoptosis through CIP2A-mediated pathway | Chao T.-T.; Wang C.-Y.; Lai C.-C.; Chen Y.-L.; Tsai Y.-T.; Chen P.-T.; Lin H.-I.; Huang Y.-C.T.; Shiau C.-W.; CHONG-JEN YU ; Chen K.-F. | Journal of Pharmacology and Experimental Therapeutics | 28 | 28 | |
2021 | TD-92, a novel erlotinib derivative, depletes tumor-associated macrophages in non-small cell lung cancer via down-regulation of CSF-1R and enhances the anti-tumor effects of anti-PD-1 | Shih C.-T.; Shiau C.-W.; Chen Y.-L.; Chen L.-J.; Chao T.-I.; Wang C.-Y.; CHAO YUAN HUANG ; Hung M.-H.; Chen K.-F. | Cancer Letters | 14 | 10 |